stockrowCareDx, Inc.
CDNA Healthcare Diagnostics & Research
CareDx, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $379.8 million, up 13.8% from fiscal 2024.
- Revenue
- +39.3%
- EPS
- +1,133.3%
- Free cash flow
- −68.6%
Quarter to September 2026, against a year earlier
Follow CDNA
Alert me
CareDx, Inc. (CDNA) Shares outstanding
CareDx, Inc.'s shares outstanding at the end of fiscal 2025 was $53.3M, down 5.89% from $56.6M in fiscal 2024. At the end of the quarter to 30 September 2026 it was $55.0M. Over the past ten years it has ranged from $11.9M (fiscal 2015) to $56.6M (fiscal 2024); the current reading is higher than 73% of that period. CareDx, Inc. ranks 25th of 49 Diagnostics & Research companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $53.3M | (5.89%) |
| FY2024 | $56.6M | 5.31% |
| FY2023 | $53.8M | 0.83% |
| FY2022 | $53.3M | 2.07% |
| FY2021 | $52.2M | 12.39% |
| FY2020 | $46.5M | 10.27% |
| FY2019 | $42.2M | 18.27% |
| FY2018 | $35.6M | 52.74% |
| FY2017 | $23.3M | 41.44% |
| FY2016 | $16.5M | 39.09% |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $55.0M | 2.92% |
| Jun 2026 | $53.4M | 0.55% |
| Mar 2026 | $53.1M | (0.30%) |
| Dec 2025 | $53.3M | (0.84%) |
| 43 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| SHC Sotera Health Company compare | $289.2M |
| ADPT Adaptive Biotechnologies Corporation compare | $186.9M |
| NEO NeoGenomics, Inc. compare | $128.6M |
| VCYT Veracyte, Inc. compare | $82.8M |
| RDNT RadNet, Inc. compare | $78.7M |
| CDNA CareDx, Inc. | $55.0M |
| BLLN BillionToOne, Inc. compare | $53.7M |
| GRAL GRAIL, Inc. compare | $46.8M |
| WGS GeneDx Holdings Corp. compare | $29.7M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on CDNA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement